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soma cruzi, which is transmitted to humans through the feces of
infected bloodsucking insects in endemic areas of Latin Amer-
ica, or occasionally by nonvectorial mechanisms includingClinical Microbiology and Infection © 2015 European Society of Cpotential transmission linked to blood transfusion and organ
transplants [1].
It is estimated that 8 to 10 million people are infected by
T. cruzi worldwide [2]. Between 68 000 and 122 000 cases are
expected in Europe, with Spain being the country most affected
[3]. As a result of the shortage of organs for transplantation,
reports on the use of organs from anti–T. cruzi–positive do-
nors in noninfected recipients has increased in the literature,
especially in kidney transplantation and, less frequently, liver
transplantation. Here we describe a case of liver transplantation
from an anti–T. cruzi–positive donor to a noninfected recipient
who evolved favorably despite not having received preemptive
therapy. This is deﬁned as the treatment with benznidazole of
any patient receiving an organ from an anti–T. cruzi–positive
donor.Case reportThe patient was a Spanish woman, 52 years old, with no history
of travelling abroad, transfusions or prior surgery. She received
an orthotopic liver transplant in December 2008 due to a
primary biliary cirrhosis in terminal stage. The patient remained
asymptomatic except for acute rejection on the seventh day
after transplantation, conﬁrmed by biopsy. From trans-
plantation to June 2009, she received prednisone and tacroli-
mus, then mycophenolate and tacrolimus. The donor was a
woman from Bolivia who had lived in Spain since 2003 and who
died of stroke. Carrier status of Chagas disease was commu-
nicated from the hospital of origin 10 months after trans-
plantation, in October 2009. After receiving the epidemiological
alert, the recipient was diagnosed with Chagas disease by
positive serology using immunochromatography (Operon). A
sample was sent to the National Microbiology Centre (Instituto
de Salud Carlos III) to conﬁrm the result by determination of
anti–T. cruzi antibodies by indirect immunoﬂuorescent antibody
test and by PCR. T. cruzi DNA was detected by PCR with the
use of oligonucleotides 121–122 and Tcz1–Tcz2, which
ampliﬁed the variable region of the kinetoplast DNA minicircle
(330 bp) and a repetitive sequence of satellite DNA (195 bp),
respectively [4]. The presence of the parasite in blood was also
detected by microhematocrit.
The patient remained asymptomatic, and ECG studies, chest
x-ray, echocardiography, barium enema, oesophagogram and
brain CT were normal. Treatment was initiated with benznida-
zole (Radanil; Roche, Argentina) (5 mg/kg/day) in ascending
doses of 50 mg/2 days to reach a full dose with good tolerance.
Before starting the treatment, the patient had a blood count with
hemoglobin 10.1 g/dL, platelets 123 000/mm3 and leukocytesClin Microbiol Infect 2015; 21: 687.e1–687.e3
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including a physical examination, hematologic and biochemic
determinations, measurement of levels of immunosuppressants
and determination of presence of the parasite in blood by
microhematocrit method and PCR, was performed. Weekly
follow-up was performed after that, until the end of the treat-
ment. On the fourth day of treatment, negative results were
found via both techniques, microhematocrit and PCR, but the
patient developed severe neutropenia (160 neutrophils/mm3),
forcing the suspension of treatment and the introduction of
granulocyte colony stimulating factor. In patients with Chagas
disease, cases of neutropenia are usually mild and transitory [5],
and treatment with granulocyte colony stimulating factor is not
necessary. In this case, we followed local clinical guidelines aimed
at immunocompromised patients with severe neutropenia. After
neutrophil levels had recovered to above 1000 neutrophils/mm3,
treatment with benznidazole for 60 days was completed until the
full intended dose was attained, adding colony-stimulating factor
three times a week until the end of treatment. Follow-up was
carried out every 6 months during the ﬁrst 2 years after infec-
tion, then annually with a study protocol that included serology,
PCR, ECG and echocardiography. During the monitoring period,
the patient showed no clinical or laboratory abnormalities, and T.
cruzi DNA was not detected in 21 sequential PCR tests. After 2
years of infection, serology became negative, until the last review
in February 2015.
The shortage of suitable organ donors for transplantation has
stimulated the use of organs from donors with transmissible
infections such as Chagas disease in noninfected recipients.
Although there is experience in kidney transplantation [6,7],
the cases of successful liver transplantation are scarce, and in
most of them, the patients received preemptive therapy
immediately after surgery and during the following 14 days [8].
Following the same strategy, two cases of liver transplantation
from anti–T. cruzi–positive donors to seronegative recipients
have been published in Spain, with good results [9]. However,
some authors proposed that anti–T. cruzi–positive donors may
be accepted for liver transplant recipients only in emergency
situations [10].
McCormack et al. [11] described the results of a protocol
using livers from anti–T. cruzi–positive donors without pre-
ventive therapy. In that study, only 22% of patients became
infected by T. cruzi; they had no clinical symptoms and experi-
enced a good evolution after early benznidazole treatment.
However, despite the good clinical evolution of our patient,
there are certain differences between this case and others re-
ported in the literature. Firstly, although Chagas disease in
immunocompromised patients may present with severe clinical
manifestations such as myocarditis and/or encephalitis accom-
panied with high morbidity and mortality, these symptoms areClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectrarely seen. A possible explanation is the use of preventive
treatments immediately after transplantation or the realization
of close analytical controls during the subsequent monitoring
period. However, it is remarkable that our patient remained
asymptomatic for 9 months after transplantation without
serious complications. Secondly, in these patients, there is a
concomitant use of immunosuppressant drugs as mycopheno-
late and antiparasitic drugs (benznidazole, nifurtimox) used in
Chagas disease. Our patient was treated with benznidazole, the
adverse effects of which include development of neutropenia
and altered liver function. Thus, the severe neutropenia
developed by our patient may be aggravated by the concomi-
tant use of immunosuppressants [12]. Little is known about the
interactions between these drugs [12], but this could be a
limiting factor in treating these patients, either due to poten-
tiation of adverse effects or because potential interactions may
decrease the levels of immunosuppressants and increase the
possibility of transplant rejection.
In this patient, the period from transplantation to diagnosis
of T. cruzi infection was 9 months. This was due to a late
diagnosis of the infection in the donor. Although the patient
remained asymptomatic and ﬁnally had a good therapeutic
response, given the lack of experience and the unpredictability
of the clinical course of these patients, clinical guidelines and
clear policies are necessary to avoid these mismatches [13,14].
There are a range of transplantation policies in Europe, and not
all European countries have the same guidelines, although
current legislation allows organs to be trafﬁcked between Eu-
ropean countries. Moreover, at present, as a result of the
economic crisis, immigrants from Latin America residing in
Spain are moving to other European countries [13]. In general
terms, a uniﬁcation of European policies regarding the use of
organs in these groups is necessary.
Other important points in these patients are the follow-up
and the diagnostic tests used to conﬁrm or exclude T. cruzi
infection. In immunocompetent patients in the acute phase, the
diagnosis can be made by direct parasitologic techniques, such as
direct visualization of the parasite. In chronic phases, the pres-
ence of two positive serological tests performed by different
techniques is required. Transplant recipients, as has occurred in
other immunocompromised patients, may have no serocon-
version and/or an early loss of antibodies due to immunosup-
pressive treatment. For this reason, performing sequential PCR
in these patients is particularly useful, both in the early diagnosis
and long-term monitoring [14]. Moreover, PCR may also detect
the presence of the parasite before classical parasitologic tests
and before clinical symptoms appear [15–17].
In conclusion, transplantation of livers from anti–T. cruzi–
positive donors may be useful, given the shortage of available
organs for patients who are in terminal stages of their illness,ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 687.e1–687.e3
CMI Rodriguez-Guardado et al. T. cruzi infection 687.e3but it is not a risk-free practice. Although many unknown points
about treatment and their interactions with immunosuppres-
sants, both in the diagnosis and follow-up, remain unclear, we
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